Absci (ABSI) Shares Outstanding (2020 - 2026)
Absci (ABSI) posted Shares Outstanding (Entity) of $155.9 million for Q1 2026, up 2.9% sequentially from $151.5 million in Q4 2025, and up 22.22% YoY from $127.6 million in Q1 2025.
Analysis
Absci (ABSI) Shares Outstanding (2020 - 2026) Analysis & Trends
Absci has reported Shares Outstanding (Entity) for 7 years, with the latest figure at $155.9 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 22.22% year-over-year to $155.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $155.9 million (up 22.22% YoY) and the FY2025 annual result came in at $151.5 million, up 31.34% from the prior year.
- Shares Outstanding (Entity) climbed to $155.9 million in Q1 2026 per ABSI's latest filing, from $151.5 million in the prior quarter.
- Over five years, Shares Outstanding (Entity) peaked at $155.9 million in Q1 2026 and troughed at $92.4 million in Q4 2022.
- A 5-year average of $113.7 million and a median of $113.0 million in 2024 frame the typical range for Shares Outstanding (Entity).
- The sharpest annual moves came in 2022 and 2023: Shares Outstanding (Entity) surged 425.94% in 2022, then retreated 0.38% in 2023.
- Over 5 years, Shares Outstanding (Entity) stood at $92.4 million in 2022, then rose by 0.73% to $93.1 million in 2023, then gained by 23.93% to $115.4 million in 2024, then surged by 31.34% to $151.5 million in 2025, then advanced by 2.9% to $155.9 million in 2026.
- According to Business Quant data, Shares Outstanding (Entity) over the past three periods registered $155.9 million, $151.5 million, and $150.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.77 Bn | 130.92 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.51 Bn | 77.52 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 61.30 Mn |
| 4 | Moderna | 58.20 Bn | 53.06 Bn | 52.00 Mn | 398.00 Mn |
| 5 | Revolution Medicines | 44.04 Bn | 44.04 Bn | - | 210.89 Mn |
| 6 | BeOne Medicines | 39.99 Bn | 34.89 Bn | 1.53 Bn | 111.58 Mn |
| 7 | Alnylam Pharmaceuticals | 35.45 Bn | 32.14 Bn | 992.69 Mn | 133.61 Mn |
| 8 | Royalty Pharma | 28.40 Bn | 27.56 Bn | - | 445.06 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | 157.47 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 157.47 Mn |
| Mar 31, 2026 | 152.96 Mn |
| Dec 31, 2025 | 136.78 Mn |
| Sep 30, 2025 | 143.77 Mn |
| Jun 30, 2025 | 127.59 Mn |
| Mar 31, 2025 | 124.46 Mn |
| Dec 31, 2024 | 110.24 Mn |
| Sep 30, 2024 | 113.61 Mn |
| Jun 30, 2024 | 112.93 Mn |
| Mar 31, 2024 | 99.39 Mn |
| Dec 31, 2023 | 92.03 Mn |
| Sep 30, 2023 | 92.22 Mn |
| Jun 30, 2023 | 91.83 Mn |
| Mar 31, 2023 | 91.48 Mn |
| Dec 31, 2022 | 90.85 Mn |
| Sep 30, 2022 | 91.11 Mn |
| Jun 30, 2022 | 90.67 Mn |
| Mar 31, 2022 | 90.27 Mn |
| Dec 31, 2021 | 49.69 Mn |
| Sep 30, 2021 | 73.29 Mn |